{"entity":{"id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of SHR-8068, Adebrelimab, Bevacizumab in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","summary":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer is a phase 2 interventional study registered as NCT07071714 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 103 participants enrolled, started 2025-07-22 and due to reach its primary completion in 2031-10. Interventions recorded: SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07071714","url":"https://clinicaltrials.gov/study/NCT07071714"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-8068","adebrelimab","bevacizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07071714","phase":"2","setting":"An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","participation":[{"nct":"NCT07071714","source":"https://clinicaltrials.gov/study/NCT07071714","fetchedAt":"2026-10-07T16:55:23.338Z","studySha256":"b5df755ee1b54a40cc2aa5b09f6f22c33c129c63d8327719abc938459797e7b4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-11","leadSponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":103,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-07-22","startedType":"actual","enrolled":103,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07071714/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}